Novavax, Inc. Initiates Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC